Exploring Novel Endpoints for Clinical Trials in Kidney Disease: Challenges and Opportunities

Kidney International Reports

Volumn 2, Issue 3, 2017, Pages 295-296

  Roy Chaudhury, Prabir ^a,b,c  

^a UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85024913280     PISSN: 24680249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ekir.2017.04.001     Document Type: Editorial

References (6)

1. Strippoli, G.F., Craig, J.C., Schena, F.P., The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15 (2004), 411–419.
2. Taylor, P.C., Keystone, E.C., van der Heijde, D., et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376 (2017), 652–662.
3. Perrone, R.D., Mouksassi, M.-S., Romero, K., et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2 (2017), 442–450.
4. Perrone, R.D., Mouksassi, M.-S., Romero, K., et al. A drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2 (2017), 451–460.
5. Levey, A.S., Inker, L.A., Matsushita, K., et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64 (2014), 821–835.
6. Linde, P.G., Archdeacon, P., Breyer, M.D., et al. Overcoming barriers in kidney health-forging a platform for innovation. J Am Soc Nephrol 27 (2016), 1902–1910.